As recently as 2016, Swedish Orphan Biovitrum, or Sobi, was largely a specialty pharmaceutical firm in-licensing rights to market drugs in Europe. Since then, the successful launches of hemophilia ...
2. Items affecting comparability (IAC). For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information is information that ...
Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to ...
Sanofi and Sobi's haemophilia partnership has been under competitive pressure from new therapies like Roche's antibody Hemlibra, so the two companies are hoping a new long-acting drug candidate ...
<div class="audio-player js-audio"> <div class="audio-player__inner"> <div class="audio-player__icons"> <a class="audio-player__start js-audioStopPlay" href="#"> <svg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback